Mafalda Oliveira, MD, PhD
Medical Oncology Department
Breast Cancer Group
Vall d'Hebron University Hospital
Identifying new therapeutic options for a subgroup of advanced hormone receptor (HR)-positive breast cancer patients.
While hormone receptor(HR)-positive breast cancers tend to have a good prognosis and respond well to therapy, a subset of HR-positive breast cancers tend to be more aggressive. In this subtype the HER2 gene is activated, but HER2 protein (which is the target of HER2-targeted therapies), is not detected. These are therefore distinguished from HER2-postive breast cancer with the classification of HER2-enriched (HER2-E) and comprise about one in five patients with HR-positive/HER2-negative advanced disease. Clinically, these breast cancers have a poor survival rate and are resistant to both endocrine therapy and CDK4/6 inhibitors. The androgen receptor—a primary target in the treatment of prostate cancer—is present on many HR-positive breast cancers, and HER2-E tumors appear to exhibit an addiction to AR. Dr. Oliveira and her team are conducting a clinical trial in patients with HR-positive/HER2-E metastatic breast cancer to see if AR-inhibiting drugs can improve treatment response in these patients.
The team uses the PAM50 diagnostic assay to identify patients with metastatic breast cancer whose tumors are classified as HR-positive/ HER2-E. The trial will test if the AR-targeting drug, enzalutamide, can stop tumor cell growth in these patients after 2 weeks, and then patients will continue on therapy for as long as it is successful. Almost half of a total of 40 patients are enrolled in the study.
All eight study sites are open, and the trial aims to complete patient enrollment by mid-late 2022.
Mafalda Oliveira MD, PhD, is a medical oncologist at the Medical Department of the Vall d'Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona since 2011. She has completed a master’s in clinical research in June 2013 and a PhD in Medicine in July 2017, both at the Universidad Autònoma de Barcelona.
Dr. Oliveira’s research interest focuses in the study of the molecular alterations and evolution of metastatic breast cancer, in the clinical development of new drugs (especially by designing clinical trials with innovative biological hypotheses), and in the application of liquid biopsies as diagnostic, predictive, and prognostic tools in breast cancer. She is involved as Principal Investigator in multiple phase I, phase II, and phase III clinical trials in breast cancer, with drugs that target the PI3K/AKT/mTOR pathway, CDK4/6 inhibitors, oral SERDs, new epigenetic drugs, ADCs, and cancer immunotherapy drugs.
She is also a member of the Executive Board and the Scientific Committee of SOLTI-Breast Cancer Research Group (an academic cooperative research group based in Spain), and a member of ASCO, ESMO, SEOM, and AACR.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.